<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959981</url>
  </required_header>
  <id_info>
    <org_study_id>ERAS-007-02</org_study_id>
    <nct_id>NCT04959981</nct_id>
  </id_info>
  <brief_title>A Study of ERAS-007 in Patients With Advanced Non-Small-Cell Lung Cancer</brief_title>
  <acronym>HERKULES-2</acronym>
  <official_title>A Phase 1b/2, Open-Label, Multicenter Study of ERAS-007 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasca, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasca, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination&#xD;
           with other cancer therapies in study participants with advanced non-small cell lung&#xD;
           cancer (NSCLC).&#xD;
&#xD;
        -  To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007&#xD;
           administered in combination with other cancer therapies.&#xD;
&#xD;
        -  To evaluate the antitumor activity of ERAS-007 in combination with other cancer&#xD;
           therapies.&#xD;
&#xD;
        -  To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in&#xD;
           combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open-label, multicenter clinical study evaluating ERAS-007 in&#xD;
      combination with other cancer therapies in study participants with advanced NSCLC. This study&#xD;
      will serve as a platform study, allowing for evaluation of safety/tolerability and efficacy&#xD;
      of ERAS-007 in combination with other cancer therapies. The study will initially commence&#xD;
      with dose escalation of ERAS-007 administered once weekly (QW) in combination with&#xD;
      osimertinib in study participants with advanced NSCLC harboring an epidermal growth factor&#xD;
      receptor-sensitizing mutation (EGFRm). Dose expansion will follow and will test ERAS-007&#xD;
      administered at the RD identified from dose escalation, in combination with osimertinib in&#xD;
      study participants with EGFRm NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Study Day 1 up to Day 22</time_frame>
    <description>Based on adverse events observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Study Day 1 up to Day 22</time_frame>
    <description>Based on adverse events observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Dose (RD)</measure>
    <time_frame>Study Day 1 up to Day 22</time_frame>
    <description>Based on adverse events observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Incidence and severity of treatment-emergent AEs and serious AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration (Cmax)</measure>
    <time_frame>Study Day 1 up to Day 22</time_frame>
    <description>Maximum plasma concentration of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Cmax (Tmax)</measure>
    <time_frame>Study Day 1 up to Day 22</time_frame>
    <description>Time to achieve maximum plasma concentration of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Study Day 1 up to Day 22</time_frame>
    <description>Area under the plasma concentration-time curve of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life</measure>
    <time_frame>Study Day 1 up to Day 22</time_frame>
    <description>Half-life of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Non-squamous Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (Part 1): ERAS-007 QW plus osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 will be orally administered QW in combination with osimertinib to study participants with advanced EGFRm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part 2): ERAS-007 QW plus osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with osimertinib to study participants with advanced EGFRm NSCLC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERAS-007</intervention_name>
    <description>ERAS-007 will be administered orally as specified in Arm description.</description>
    <arm_group_label>Dose Escalation (Part 1): ERAS-007 QW plus osimertinib</arm_group_label>
    <arm_group_label>Dose Expansion (Part 2): ERAS-007 QW plus osimertinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>osimertinib</intervention_name>
    <description>80 mg orally once daily</description>
    <arm_group_label>Dose Escalation (Part 1): ERAS-007 QW plus osimertinib</arm_group_label>
    <arm_group_label>Dose Expansion (Part 2): ERAS-007 QW plus osimertinib</arm_group_label>
    <other_name>Tagrisso</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Willing and able to give written informed consent.&#xD;
&#xD;
          -  Have histologically or cytologically confirmed advanced NSCLC harboring EGFR&#xD;
             mutation(s) sensitive to EGFR inhibitors at initial diagnosis per local approved&#xD;
             label.&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
          -  Adequate bone marrow and organ function.&#xD;
&#xD;
          -  Have ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Willing to comply with all protocol-required visits, assessments, and procedures.&#xD;
&#xD;
          -  Able to swallow oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent treatment with any systemic anticancer therapy for NSCLC, including any&#xD;
             approved or investigational agent.&#xD;
&#xD;
             • Prior therapy with a RAS, RAF, MEK, or ERK inhibitor.&#xD;
&#xD;
          -  Prior cancer immunotherapy (CIT) (e.g., immune checkpoint inhibitors), unless the CIT&#xD;
             was followed by a non-CIT containing regimen prior to study enrollment&#xD;
&#xD;
               -  Anticancer treatment within 21 days of enrollment, except for osimertinib which&#xD;
                  may be continued during the screening period.&#xD;
&#xD;
               -  Palliative radiotherapy within 7 days of enrollment.&#xD;
&#xD;
          -  History of unacceptable toxicity to treatment with osimertinib.&#xD;
&#xD;
             • Major surgery within the 28 days of enrollment.&#xD;
&#xD;
          -  Unresolved toxicities from prior systemic therapy greater than NCI CTCAE grade 1 at&#xD;
             time of enrollment, except alopecia and grade 2 neuropathy due to prior chemotherapy.&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic disease or evidence of any other&#xD;
             significant clinical disorder or laboratory finding that renders the patient&#xD;
             inappropriate to participate in the study.&#xD;
&#xD;
          -  Impaired cardiovascular function or clinically significant cardiovascular disease.&#xD;
&#xD;
          -  History or current evidence of retinal pigment epithelial detachment (RPED), central&#xD;
             serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or&#xD;
             RVO.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Contraindication to osimertinib use as per local label.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Komatsubara, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Senior Medical Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erasca Clinical Team</last_name>
    <phone>18584656511</phone>
    <email>clinicaltrials@erasca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center (John Theurer Cancer Center)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Tennessee Oncology)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>epidermal growth factor receptor</keyword>
  <keyword>mutation</keyword>
  <keyword>biomarker</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Tagrisso</keyword>
  <keyword>osimertinib</keyword>
  <keyword>ERK</keyword>
  <keyword>MAPK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

